Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05563818
Other study ID # HIK-WL-SCZ-2021-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 9, 2021
Est. completion date December 20, 2022

Study information

Verified date February 2023
Source Hikma Pharmaceuticals LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Brief Summary: Definition: A short description of the clinical study, including a brief statement of the clinical study's hypothesis, written in language intended for the lay public. Limit: 5000 characters. The purpose of this study is to investigate the relationship between speech features and severity of positive and negative clinical symptoms in Arabic speaking patients with schizophrenia. Individuals will be invited to participate in this study because (1) they have a confirmed clinical diagnosis of schizophrenia; (2) they plan to receive routine clinical care for schizophrenia at one of the four participating sites; (3) they speak Arabic as a first language. Participants must be between the ages of 18-65 years. Participation will involve seven visits consisting of one baseline visit and six monthly follow-up visits. All participants will continue to receive routine clinical care. Participation in this research will involve providing speech samples using standardized tasks collected using an electronic device. Additionally, study team members will assess positive and negative symptoms of schizophrenia using validated questionnaires.


Description:

Speech disorganization is a key feature of schizophrenia. The development of computerized tools to assess speech disorganization is rapidly growing in schizophrenia research. Several early studies showed that changes in speech distinguish schizophrenia patients from healthy controls and assist in differential diagnostics and relapse prevention (1). The Winterlight app can be used for speech collection and assessment and uses speech-based artificial intelligence to identify vocal biomarkers capable of detecting changes in cognitive/clinical symptoms. Symptom rating scales remain the primary mode of assessing the nature and severity of schizophrenia and the magnitude of any change over time. The Positive and Negative Symptom Scale (PANSS) is a 30-item rating scale that was developed to measure the symptom severity of patients with schizophrenia and assess their dimensions (2). It has been widely used in clinical trials of schizophrenia and is considered as the "gold standard" for the assessment of antipsychotic treatment efficacy. The goal of this study is to test the hypothesis that quantitative measures derived from speech samples acquired using the Winterlight application will be associated with positive and negative symptom subscores as assessed by the PANSS. The investigators will use speech-based artificial intelligence methods to identify aspects of voice and language that are related to schizophrenia symptoms in Arabic-speaking patients. Data collected may be used to evaluate: 1. The relationship between speech measures and PANSS subscores at baseline. 2. The relationship between changes in speech measures and changes in positive symptoms over time. 3. The relationship between changes in speech measures and changes in negative symptoms over time. 4. The ability for speech measures to be used to predict psychotic relapse in individuals with schizophrenia. 5. The feasibility of predicting relapse based on speech and sociodemographic variables.


Recruitment information / eligibility

Status Completed
Enrollment 57
Est. completion date December 20, 2022
Est. primary completion date December 20, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Aged 18 - 65 years 2. Confirmed clinical diagnosis of schizophrenia as per the DSM-5 criteria, at any stage of disease. 3. Planned to receive routine clinical care for schizophrenia in the study site for the next 6 months. 4. Arabic is first language Exclusion Criteria: 1. Illiterate. 2. Catatonic schizophrenia subtype. 3. Neurological disorder or major health problem. 4. Severe substance use disorder using DSM-5 criteria. 5. Risk to self or others. 6. Patient with any speech disorder or treated/planned to be treated with any medication known to impact speech (e.g. first-generation antipsychotics) 7. Patient or family member is unable to provide consent to participate in the study. 8. Participation in another clinical study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
WinterLight Mobile Phone Speech Analysis
N/A- observational study

Locations

Country Name City State
Algeria Mustapha University Hospital Algiers
Egypt Ain Shams Hospital Cairo
Jordan Mental Health Hub Amman
Saudi Arabia Jeddah Psychiatry Hospital Jeddah

Sponsors (2)

Lead Sponsor Collaborator
Hikma Pharmaceuticals LLC Winterlight Labs

Countries where clinical trial is conducted

Algeria,  Egypt,  Jordan,  Saudi Arabia, 

References & Publications (2)

de Boer JN, Brederoo SG, Voppel AE, Sommer IEC. Anomalies in language as a biomarker for schizophrenia. Curr Opin Psychiatry. 2020 May;33(3):212-218. doi: 10.1097/YCO.0000000000000595. — View Citation

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Speech features derived from the Winterlight Assessment (WLA). Acoustic and linguistic measures of speech acquired using the Winterlight Application up to month 6
Primary Positive and Negative Syndrome Scale (PANSS) including total score, positive subscore, negative subscore and psychopathology subscore. 30-item clinical scale to assess positive and negative symptoms severity in people with schizophrenia. up to month 6
Secondary Change in speech features derived from the Winterlight Assessment (WLA). Baseline to endpoint (6 month) change on acoustic and linguistic measures of speech computed based on the WLA. Change from baseline to month 6
Secondary Change in Positive and Negative Syndrome Scale (PANSS) including total score, positive subscore, negative subscore and psychopathology subscore. score measured by the PANSS positive sub-score Baseline to endpoint (6 month) change on 30-item clinical scale to assess positive and negative symptoms severity in people with schizophrenia Change from baseline to month 6
Secondary Incidence of psychotic relapse Psychotic relapse is defined as: hospitalization, suicidal/homicidal ideation, violent behavior, a 25% increase in the PANSS total score, or a significant increase in at least one of several pre-specified PANSS items. Change from baseline to month 6
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A